AI assistant
Sending…
Monopar Therapeutics — Director's Dealing 2025
Dec 8, 2025
32883_dirs_2025-12-08_ab196f06-ead0-4b77-95d8-20e1be6b3ab9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2025-12-02
Reporting Person: Robinson Chandler (Director, Chief Executive Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-12-02 | Stock Options | $75.94 | A | 16753 | Acquired | 2035-12-02 | Common Stock (16753) | Direct |
| 2025-12-02 | Restricted Stock Units | $0 | A | 49133 | Acquired | Common Stock (49133) | Direct |
Footnotes
F1: Options vest 6/48ths on June 30, 2026, and 1/48th per month thereafter.
F2: RSUs vest 6/48ths on June 30, 2026, and 3/48ths per quarter thereafter.
More from Monopar Therapeutics
Regulatory Filings
2026
May 29
Regulatory Filings
2026
May 19
Interim / Quarterly Report
2026
May 14
Report Publication Announcement
2026
May 14
Annual Report
2026
Apr 30
Regulatory Filings
2026
Apr 20
Annual Report
2026
Apr 1
Annual Report
2026
Mar 27
Director's Dealing
2026
Mar 4
Board/Management Information
2026
Mar 2